Loading
CP
Citius Pharmaceuticals, Inc. Stock: price and insider trades · United States
US·Mcap US$18.7M
Citius Pharmaceuticals, Inc.: what insiders have been doing
Insider filings for Citius Pharmaceuticals, Inc. are scarce in the SEC (Form 4) feed, the latest one published on 30 August 2024. This page will fill in as new trades are disclosed. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
2
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended September 2025 · cache
US$0.68
Analyst consensus
1 analysts1.00/5
US$4.00Target US$4.00(+486%)US$4.00
Income statement
RevenueUS$77.5k
EBITDA-US$38.2M-49298% margin
Net income-US$37.4M0.0% margin
Valuation
PER (forward)-0.8x
P/Book0.2x
Beta0.99
Balance sheet & cash
Market capUS$18.7M
Total debtUS$1.8M
Free Cash Flow-US$26.6M
Debt / Equity1%
Profitability & ownership
ROE-83.6%
ROA-27.6%
% insiders1.8%
% institutions4.2%
Last declaration on 30 August 2024
Declarations2 total
2,415 shares@ US$0.015100.0% of flowCommon StockSEC:0001213900-24-074506:0
12,071 shares@ US$0.015100.0% of flowCommon StockSEC:0001213900-24-074505:0
2 of 2 declarations
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative treatments for serious medical conditions. It is listed on NASDAQ under the ticker CTXR.
